ACCESS Newswire

Northway Biotech

24.5.2023 18:24:40 CEST | ACCESS Newswire | Press release

Share
Northway Biotech Set to Launch Advanced Microbial and Mammalian GMP Facilities in Massachusetts

WALTHAM, MA / ACCESSWIRE / May 24, 2023 / Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
Northway Biotech Set to Launch Advanced Microbial and Mammalian GMP Facilities in Massachusetts

This recent growth is an extension of the successful launch of Northway Biotech's process and analytical development laboratories in Waltham (Greater Boston area) in 2020. The expanded facility now includes state-of-the-art cGMP suites, marking a significant milestone in the company's journey. The newly established cutting-edge biomanufacturing suites host a microbial fermentation train with up to 450 liters of volume capacity, and a mammalian production train with the ability to handle volumes of up to 2,000 liters. Northway Biotech has further established a specialized, fully automated fill and finish line to accommodate its clients' varied needs, supporting high-throughput filling into vials, syringes, and cartridges.

Prof. Vladas Algirdas Bumelis, CEO of Northway Biotech, shared his insights regarding this accomplishment, stating, "The addition of GMP suites in our US site represents a transformative step for our organization, enabling us to provide comprehensive end-to-end solutions from our second site now. We are poised to transition current process development projects into the cGMP manufacturing phase in a timely manner, in line with our clients' committed schedules. Additionally, our longstanding US partners who have engaged with our Lithuanian site can now also take advantage of the geographical convenience of our modern facilities located in the Greater Boston Area. With our fully functional and technologically advanced manufacturing site at our disposal, Northway Biotech is perfectly positioned to take on manufacturing projects aimed at both clinical and commercial supply."

To commemorate this significant expansion and express gratitude to its valued partners and industry leaders, Northway Biotech will be hosting a grand opening event for its cGMP suites on June 8. This event promises to be an occasion of celebration and networking, providing an opportunity for attendees to witness firsthand the state-of-the-art facilities and engage in meaningful discussions within the biotech community.

About Northway Biotech - https://www.northwaybiotech.com

Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately-owned company founded in 2004 and located in Vilnius, Lithuania; London, United Kingdom; and Waltham, Massachusetts, United States.

For Further Information, Contact:

Prof. Vladas Algirdas Bumelis
CEO and Chairman of the Board
Northway Biotech
vladas.bumelis@northwaybiotech.com

Contact Information

Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com

SOURCE: Northway Biotech

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View source version on accesswire.com:
https://www.accesswire.com/757061/Northway-Biotech-Set-to-Launch-Advanced-Microbial-and-Mammalian-GMP-Facilities-in-Massachusetts

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

The Numbers are Clear: Latest Iteration of Stagwell's News Advertising Study Shows Germans Love Their News18.2.2026 11:00:00 CET | Press release

Stagwell, Axel Springer, Teads and The Trade Desk partner on German News Advertising Study, drawing insights from over 11,000 respondents Study finds the proportion of ‘news junkies' in Germany is highest of all the surveyed markets BERLIN, GERMANY / ACCESS Newswire / February 18, 2026 / Stagwell, the global challenger network transforming marketing through AI, released the latest installment of its News Advertising Study in partnership with Axel Springer, Teads and The Trade Desk. The survey, fielded among 11,282 adults in Germany, builds on Stagwell's prior News Advertising studies conducted in Asia Pacific, Canada, the U.S. and UK. This regional study further reinforces it is safe for brands to advertise adjacent to quality news content agnostic of the topic. "The Future of News research for the German market illustrates how important it is for brands to advertise in quality news publications. Germany has a 10-percentage point higher share of news enthusiasts than other markets, and

Kraft Heinz, Braskem, and Tenaris to headline OMP Conference São Paulo 202617.2.2026 15:00:00 CET | Press release

Global industry leaders showcase real-world results and AI-driven supply chain planning innovations SÃO PAULO, BR / ACCESS Newswire / February 17, 2026 / OMP, a leading provider of AI-powered supply chain planning solutions, brings its REAL conference series to Latin America with a one-day event in São Paulo on April 16, 2026. The conference will bring together Fortune 500 leaders to share how they are transforming global operations through digital innovation. Under the theme "Real expertise. Real solutions. Real results," the conference focuses on the practical application of AI in complex supply chain environments. The agenda is anchored by three global powerhouses who will provide a "behind-the-scenes" look at their digital transformation journeys in partnership with OMP's Unison Planning™: Kraft Heinz, a global food and beverage company, will demonstrate how data-driven planning, AI-enabled optimization, and end-to-end visibility are building a more agile and sustainable value chai

Supported by U.S. Polo Assn., the 2026 U.S. Open Women's Polo Championship(R) Concludes with Victory Eastern Hay the Champion17.2.2026 13:00:00 CET | Press release

WEST PALM BEACH, FL / ACCESS Newswire / February 17, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), proudly supported the 2026 U.S. Open Women's Polo Championship®, which concluded on February 15 at the USPA National Polo Center (NPC) in Wellington, Florida, on the iconic U.S. Polo Assn. Stadium Field. Widely regarded as the most prestigious women's polo tournament in the United States, the championship brought together the sport's top athletes for three weeks of elite competition at the heart of American polo.1. Victory Eastern Hay proudly displaying their trophy as winner of the 2026 U.S. Open Women's Polo Championship at the USPA National Polo Center 2. Victory Eastern Hay Team on horseback (#1 Rebecca Schmeits, #2 Aspen Tinto, #3 Hazel Jackson, #4 Milly Hine) at the 2026 U.S. Open Women's Polo Championship 3. La Dolfina Team presents a donation to their charity of choice, Polo Players Support Group, provided by U.S. Polo Assn., at th

Camino Intercepts High-Grade Copper with 83.5m at 0.94% Cu including 7.1m at 2.13% Cu at Los Chapitos, Peru17.2.2026 12:00:00 CET | Press release

VANCOUVER, BC / ACCESS Newswire / February 17, 2026 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company")is pleased to announce the exploration results from Phase 1 of the recent drilling campaign at its Los Chapitos copper project ("Los Chapitos" or the "Project") in Peru. This news release reports the results from eight drill holes completed along the Diva trend corridor, where drilling activities focused on several targets with the objective of expanding the known mineralized body and improving the understanding of the scale and continuity of the mineralized system. Los Chapitos is Camino's second copper project with partner Nittetsu Mining Co, Ltd. ("Nittetsu"), who is completing a 35% earn-in interest in Los Chapitos after investing CAD $10 million and after the completion of Phase 2 of the current drilling campaign (see news release dated June 14, 2023). Camino is also advancing its Puquios Copper Project in Chile with Nittetsu Mining towards mine cons

Datavault AI Updates Revenue Estimates by Approximately 30% at $38M to $40M17.2.2026 12:00:00 CET | Press release

PHILADELPHIA, PA / ACCESS Newswire / February 17, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, today announced its updated preliminary (unaudited) fiscal year 2025 revenue is estimated to be $38 to $40 million, exceeding its prior estimate of $30 million by up to 33%. At its midpoint, estimated FY-25 revenue represents approximately 1,300% growth year-over-year The Company attributed this revenue growth to its customer tech-licensing fees, and its Data Science Group's tokenization and monetization services. Further, Datavault AI reaffirmed its anticipated FY-26 revenue of $200 million, which, if achieved, would represent a year-over-year increase of 400% to 440%. KEY FINANCIAL METRICS FY 2025 (Preliminary, Unaudited): Estimated Revenue: $38-$40 million Prior Estimate: $30 million Incremental Change: +$8-$10 million (+27% to +33%) Midpoint:

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye